Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors. Issue 11 (11th September 2022)

• Record Type: Journal Article
• Authors: Imai, Mitsuho; Nakamura, Yoshiaki; Sunami, Kuniko; Kage, Hidenori; Komine, Keigo; Koyama, Takafumi; Amano, Toraji; Ennishi, Daisuke; Kanai, Masashi; Kenmotsu, Hirotsugu; Maeda, Takahiro; Morita, Sachi; Sakai, Daisuke; Bando, Hideaki; Makiyama, Akitaka; Suzuki, Tatsuya; Hirata, Makoto; Kohsaka, Shinji; Tsuchihara, Katsuya; Naito, Yoichi; Yoshino, Takayuki
• Is Part Of: Cancer science. Volume 113:Issue 11(2022)
• Page Start: 3646
• Page End: 3656
• Publication Date: 2022-09-11
• Subjects: circulating tumor DNA -- comprehensive genomic profiling -- liquid biopsy -- precision oncology -- solid tumor; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.15504
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false negatives due to low levels of plasma circulating tumor deoxyribonucleic acid and false positives caused by clonal hematopoiesis. Nevertheless, no guidelines and recommendations fully address these issues. Here, an expert panel committee involving representatives from 12 Designated Core Hospitals for Cancer Genomic Medicine in Japan was organized to develop expert consensus recommendations for the use of circulating tumor deoxyribonucleic acid‐based comprehensive genomic profiling. The aim was to generate guidelines for clinicians and allied healthcare professionals on the optimal use of the circulating tumor DNA assays in advanced solid tumors and to aid the design of future clinical trials that utilize and develop circulating tumor DNA assays to refine precision oncology. Fourteen clinical questions regarding circulating tumor deoxyribonucleic acid comprehensive genomic profiling including the timing of testing and considerations for interpreting results were established by searching and curating associated literatures, and corresponding recommendations were prepared based on the literature for each clinical question. Final consensus recommendations were developed by voting to determine the level of each recommendation by the Committee members. Abstract : Consensus Recommendations formulated for clinicians and allied health professionals on the optimal use of circulating tumor DNA assays in advanced solid tumors are presented. It was developed by an expert committee involving representatives from 12 Designated Core Hospitals for Cancer Genomic Medicine in Japan.